AR085132A1 - Composiciones farmaceuticas para el tratamiento de glioma maligno - Google Patents

Composiciones farmaceuticas para el tratamiento de glioma maligno

Info

Publication number
AR085132A1
AR085132A1 ARP120100357A ARP120100357A AR085132A1 AR 085132 A1 AR085132 A1 AR 085132A1 AR P120100357 A ARP120100357 A AR P120100357A AR P120100357 A ARP120100357 A AR P120100357A AR 085132 A1 AR085132 A1 AR 085132A1
Authority
AR
Argentina
Prior art keywords
treatment
glioma
maligno
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
ARP120100357A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45787254&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085132(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR085132A1 publication Critical patent/AR085132A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un producto que contiene macitentano, o una sal farmacéuticamente aceptable de este compuesto, para el uso en el tratamiento de glioma maligno en combinación con un agente terapéutico citotóxico, con radioterapia, o tanto con un agente terapéutico citotóxico como con radioterapia.Reivindicación 5: El producto de la reivindicación 4, donde el agente alquilante es temozolomida, o su sal farmacéuticamente aceptable. Reivindicación 7: El producto de la reivindicación 6, donde el inhibidor mitótico es paclitaxel o su sal farmacéuticamente aceptable.
ARP120100357A 2011-02-04 2012-02-03 Composiciones farmaceuticas para el tratamiento de glioma maligno AR085132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2011050494 2011-02-04

Publications (1)

Publication Number Publication Date
AR085132A1 true AR085132A1 (es) 2013-09-11

Family

ID=45787254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100357A AR085132A1 (es) 2011-02-04 2012-02-03 Composiciones farmaceuticas para el tratamiento de glioma maligno

Country Status (20)

Country Link
US (1) US20130310407A1 (es)
EP (2) EP2965757A1 (es)
JP (2) JP5642892B2 (es)
KR (1) KR101563069B1 (es)
CN (1) CN103327975A (es)
AR (1) AR085132A1 (es)
AU (1) AU2012213036A1 (es)
BR (1) BR112013019680A2 (es)
CA (1) CA2823994A1 (es)
CL (1) CL2013002193A1 (es)
CO (1) CO6761366A2 (es)
EA (1) EA201391131A1 (es)
IL (1) IL227747A0 (es)
MA (1) MA34952B1 (es)
MX (1) MX2013008798A (es)
SG (1) SG192600A1 (es)
TN (1) TN2013000333A1 (es)
TW (1) TW201309298A (es)
WO (1) WO2012104822A1 (es)
ZA (1) ZA201306613B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2424805C2 (ru) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
JP2013501791A (ja) 2009-08-10 2013-01-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エンドセリン受容体の阻害剤による星状細胞−腫瘍細胞の処置
CN103397308A (zh) * 2013-08-01 2013-11-20 光垒光电科技（上海）有限公司 用于mocvd设备的喷淋头
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof
KR101701619B1 (ko) 2015-06-26 2017-02-01 건양대학교산학협력단 뇌교종 세포 치료를 위한 테모졸로마이드와 비타민 d가 포함된 조성물
KR102574253B1 (ko) 2020-12-15 2023-09-07 주식회사 시선테라퓨틱스 펩티드 핵산 복합체를 유효성분으로 함유하는 교모세포종 예방 또는 치료용 조성물
CN115317604B (zh) * 2022-08-11 2023-09-22 南京脑科医院 一种靶向胶质瘤的共载放疗增敏阳离子纳米制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0116237B8 (pt) * 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
RU2424805C2 (ru) 2005-09-12 2011-07-27 Актелион Фармасьютиклз Лтд Стабильные фармацевтические композиции, включающие пиримидинсульфамид
WO2008111092A1 (en) * 2007-03-09 2008-09-18 Fresenius Kabi Oncology Limited Crystalline temozolomide monohydrate and process for preparation thereof
JP5514123B2 (ja) * 2008-02-20 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2013501791A (ja) * 2009-08-10 2013-01-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エンドセリン受容体の阻害剤による星状細胞−腫瘍細胞の処置

Also Published As

Publication number Publication date
JP2015057409A (ja) 2015-03-26
AU2012213036A1 (en) 2013-09-19
IL227747A0 (en) 2013-09-30
EP2670405B1 (en) 2015-09-02
MX2013008798A (es) 2013-10-17
CO6761366A2 (es) 2013-09-30
EP2670405A1 (en) 2013-12-11
TW201309298A (zh) 2013-03-01
ZA201306613B (en) 2015-04-29
CL2013002193A1 (es) 2014-05-09
US20130310407A1 (en) 2013-11-21
JP2014504636A (ja) 2014-02-24
CA2823994A1 (en) 2012-08-09
NZ615005A (en) 2015-10-30
MA34952B1 (fr) 2014-03-01
SG192600A1 (en) 2013-09-30
WO2012104822A1 (en) 2012-08-09
JP5642892B2 (ja) 2014-12-17
KR101563069B1 (ko) 2015-10-23
CN103327975A (zh) 2013-09-25
EP2965757A1 (en) 2016-01-13
BR112013019680A2 (pt) 2016-10-11
EA201391131A1 (ru) 2013-12-30
KR20130118981A (ko) 2013-10-30
TN2013000333A1 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
AR100006A1 (es) Derivados de tubulisina
TW201613887A (en) Antiproliferative compounds and methods of use thereof
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR077629A1 (es) Mimetico de smac
GT201300320A (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CR20140086A (es) Tratamientos de combinación para hepatitis c
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
PH12016502352A1 (en) Pharmaceutical composition
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
NZ716765A (en) Pharmaceutical combinations for the treatment of cancer
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
UY35211A (es) Compuestos tricíclicos
JP2014504636A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure